NCT00667342 - A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2008

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2017

Conditions

OsteosarcomaMalignant Fibrous Histiocytoma (MFH) of Bone

Interventions

BIOLOGICAL

Bevacizumab

Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).

DRUG

Cisplatin

Given IV.

DRUG

Doxorubicin

Given IV.

DRUG

Methotrexate

Given IV.

DRUG

Ifosfamide

Given IV.

DRUG

etoposide

Given IV.

PROCEDURE

Surgery

Participants undergo definitive surgery and assessment of histologic response at week 10.

RADIATION

Radiotherapy

Radiation therapy delivered for positive margins or intralesional resections.

Trial Locations (5)

NCI/NIH - Pediatric Oncology Branch, Bethesda

Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore

St Jude Children's Research Hospital, Memphis

Rady Children's Hospital and Health Center, San Diego

MD Anderson Cancer Center, Houston